 Mereo BioPharma Group plc NASDAQ: MREO, AIM: MPH, Mereo or the Company, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced financial results for the 12 months ended December 31, 2019. We are very pleased with the substantial operational progress we have made throughout 2019 and particularly, over the past several months, said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. 